Literature DB >> 9634043

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

P Allard1, P Bernard, Y Fradet, B Têtu.   

Abstract

OBJECTIVE: To develop a simple prognostic index for anticipating more precisely the early clinical course of primary superficial bladder cancer. PATIENTS AND METHODS: The prognostic value of patient and tumour characteristics was examined in 333 patients with primary Ta or T1 bladder cancer who participated in a multicentre prospective study already completed. Primary tumour multiplicity, a diameter of > 3 cm, stage T1, and grade 2 or 3 were independent predictors of earlier recurrence in a multivariate analysis. A simplified prognostic index consisted of the number of adverse tumour characteristics (ATCs) initially present.
RESULTS: After a median follow-up of 35.3 months, the 60 patients free of ATCs (19%) had a recurrence-free probability at 12 and 24 months of 86% and 69%, respectively, and none experienced progression. Recurrence outcomes deteriorated consistently as the number of ATCs increased among the other three groups. In patients with 3-4 ATCs, the 12- and 24-month recurrence-free probability was as low as 30% and 19%, and recurrence and tumour rates were about 2.6 times higher than in patients free of ATCs; 7% of these patients experienced progression within 35 months of follow-up.
CONCLUSION: A prognostic index based on the number of ATCs (primary tumour multiplicity, diameter > 3 cm, stage T1, and grade 2 or 3) is a strong indicator of the clinical course of superficial bladder cancer within 3 years of the first endoscopic resection. This proposal is suggested for discussion and for validation in future studies but if confirmed, this simple prognostic index may greatly help to identify indicators for adjuvant intravesical therapy and to determine the optimal periodicity of control cystoscopy regimens.

Entities:  

Mesh:

Year:  1998        PMID: 9634043     DOI: 10.1046/j.1464-410x.1998.00628.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  29 in total

1.  Validation of prognostic indices using the frailty model.

Authors:  C Legrand; L Duchateau; P Janssen; V Ducrocq; R Sylvester
Journal:  Lifetime Data Anal       Date:  2008-07-11       Impact factor: 1.588

2.  Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.

Authors:  Ashish M Kamat; Daniel L Willis; Rian J Dickstein; Rooselvelt Anderson; Graciela Nogueras-González; Ruth L Katz; Xifeng Wu; H Barton Grossman; Colin P Dinney
Journal:  BJU Int       Date:  2015-07-03       Impact factor: 5.588

Review 3.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

4.  Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.

Authors:  Weihong Ding; Shijun Tong; Yuancheng Gou; Chuanyu Sun; Hong Wang; Zhongqing Chen; Jun Tan; Ke Xu; Guowei Xia; Qiang Ding
Journal:  World J Urol       Date:  2015-04-18       Impact factor: 4.226

Review 5.  DNA methylation-based biomarkers in bladder cancer.

Authors:  Raju Kandimalla; Angela A van Tilborg; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2013-04-30       Impact factor: 14.432

6.  Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.

Authors:  Yuancheng Gou; Weihong Ding; Ke Xu; Hong Wang; Zhongqing Chen; Jun Tan; Guowei Xia; Qiang Ding
Journal:  Int Urol Nephrol       Date:  2014-11-12       Impact factor: 2.370

7.  Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.

Authors:  Woonbok Chung; Jolanta Bondaruk; Jaroslav Jelinek; Yair Lotan; Shoudan Liang; Bogdan Czerniak; Jean-Pierre J Issa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-17       Impact factor: 4.254

Review 8.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

Review 9.  Localized bladder cancer.

Authors:  J I Izawa; H B Grossman
Journal:  Curr Treat Options Oncol       Date:  2000-12

10.  Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.

Authors:  Tetsuya Yumioka; Masashi Honda; Ryoma Nishikawa; Shogo Teraoka; Yusuke Kimura; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2019-09-13       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.